Impact of multidisciplinary collaborative pharmaceutical care on knowledge, adherence, and efficacy of hormone therapy in climacteric women

Figures & data

Figure 1 Research flowchart of the study.

Table 1 Baseline characteristics of the control and intervention groups

Items	Control (n=146)	Intervention (n=150)	t-value/χ^2	P-value
Average age	47.13±7.55	45.13±6.98	1.492	0.136
Duration of symptoms	2.50±0.75	2.28±0.46	1.645	0.102
Modified KI	33.59±4.20	34.04±4.57	−0.718	0.474
BMI, n			1.874	0.599
<18.5	15	17
18.5–24.9	45	50
25–29.9	58	63
≥30	28	20
Education level, n			0.468	0.791
Primary education	15	18
Secondary education	93	90
Undergraduate/postgraduate	38	42
Exercise frequency (times/wk), n			0.293	0.588
<3	88	95
≥3	58	55

Note: Data shown as mean ± standard deviation unless indicated otherwise.

Abbreviations: BMI, body mass index; KI, Kupperman Index.

Table 2 Knowledge score of the control and intervention groups during the follow-up period

Month 3	Control (n=125)		Intervention (n=138)		z	P-value
	Mean	SD	Mean	SD
General information	59.66	31.59	77.52	23.89	−3.25	0.001*
ADR and precautions	54.05	21.52	66.33	13.15	−3.34	0.001*
Treatment options	43.76	23.04	58.17	17.92	−3.52	<0.001*
Follow-up procedures	79.66	18.39	90.46	12.42	−3.87	<0.001*
Total scores	59.28	21.11	73.12	15.17	−4.12	<0.001*
Month 6	Control (n=115)		Intervention (n=132)		z	P-value
	Mean	SD	Mean	SD
General information	67.89	25.83	83.21	20.32	−3.49	<0.001*
ADR and precautions	63.1	15.61	70.11	14.36	−1.93	0.054
Treatment options	51.44	20.32	65.07	17.32	−3.76	<0.001*
Follow-up procedures	82.33	16.36	92.11	11.12	−3.62	<0.001*
Total scores	66.19	19.01	77.63	14.13	−4.57	<0.001*
Month 12	Control (n=98)		Intervention (n=128)		z	P-value
	Mean	SD	Mean	SD
General information	70.59	25.04	85.77	21.25	−3.85	<0.001*
ADR and precautions	61.16	17.78	74.18	12.18	−3.60	<0.001*
Treatment options	51.05	22.14	68.42	18.19	−4.58	<0.001*
Follow-up procedures	83.77	17.94	94.86	8.65	−3.75	<0.001*
Total scores	66.64	17.24	80.81	13.70	−5.34	<0.001*

Note:

* Statistically significant (P<0.05).

Abbreviations: ADR, adverse drug reaction; SD, standard deviation.

Table 3 Adherence of the 2 groups, assessed by the pill count method

	Control		Intervention		Mann–Whitney U-test
	Mean	SD	Mean	SD	z	P-value
Month 3	82.17	10.95	90.97	5.25	−1.99	0.046*
Month 6	87.79	7.37	93.21	3.43	−2.43	0.014*
Month 12	93.38	5.13	95.81	6.42	−2.19	0.027*

Note:

* Statistically significant (P<0.05).

Abbreviation: SD, standard deviation.

Table 4 Modified KI scores in the control and intervention groups

	Control		Intervention		Mann–Whitney U-test
	Mean	SD	Mean	SD	z	P-value
Month 3	24.05	9.76	17.15	7.64	−3.627	<0.001*
Month 6	22.01	10.40	13.22	6.98	−3.666	<0.001*
Month 12	23.15	9.3	12.21	7.64	−4.108	<0.001*

Note:

* Statistically significant (P<0.05).

Abbreviations: KI, Kupperman Index; SD, standard deviation.